TY - JOUR
T1 - Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds
T2 - a subanalysis of the European Multicentre GHOST-EU Registry
AU - Capranzano, Piera
AU - Capodanno, Davide
AU - Brugaletta, Salvatore
AU - Latib, Azeem
AU - Mehilli, Julinda
AU - Nef, Holger
AU - Gori, Tommaso
AU - Lesiak, Maciej
AU - Geraci, Salvatore
AU - Pyxaras, Stelios
AU - Mattesini, Alessio
AU - Münzel, Thomas
AU - Araszkiewicz, Aleksander
AU - Caramanno, Giuseppe
AU - Naber, Christoph
AU - Di Mario, Carlo
AU - Sabatè, Manel
AU - Colombo, Antonio
AU - Wiebe, Jens
AU - Tamburino, Corrado
N1 - Publisher Copyright:
© 2017 Wiley Periodicals, Inc.
PY - 2018/2/15
Y1 - 2018/2/15
N2 - Background: Data on the clinical performance of bioresorbable scaffolds in patients with diabetes mellitus (DM) are still limited. The present study reported 1-year clinical outcomes associated with the use of everolimus-eluting bioresorbable vascular scaffolds (Absorb BVS; Abbott Vascular, Santa Clara, CA) in DM patients. Methods and Results: This was a subanalysis from the GHOST-EU (Gauging coronary Healing with biOresorbable Scaffolding plaTforms in Europe) multicenter retrospective registry including patients treated with Absorb BVS between November 2011 and September 2014. In this study, a comparative analysis stratified according to DM was performed. The primary endpoint was target lesion failure (TLF), defined as the combination of cardiac death, target-vessel myocardial infarction (MI) and clinically-driven target-lesion revascularization (TLR). A total of 1,477 patients were treated with 2,224 Absorb BVS; 381 (25.8%) and 1,096 (74.2%) patients were with and without DM, respectively. The 1-year rate of TLF was higher among patients with DM (7.8%) than those without DM (4.3%); the increase in TLF was driven by TLR (6.5% vs. 3.3%, P = 0.009); no significant differences in cardiac death (1.1% vs. 0.9%, P = 0.68) and target-vessel MI (3.1% vs. 2.2%, P = 0.38) were observed, respectively. Definite/probable scaffold thrombosis rate tended to be higher among patients with DM than those without DM (3.0% vs. 1.7%, P = 0.14, respectively). Conclusions: Absorb BVS use in patients with DM was associated with increased 1-year TLF and scaffold thrombosis compared with non-diabetes patients.
AB - Background: Data on the clinical performance of bioresorbable scaffolds in patients with diabetes mellitus (DM) are still limited. The present study reported 1-year clinical outcomes associated with the use of everolimus-eluting bioresorbable vascular scaffolds (Absorb BVS; Abbott Vascular, Santa Clara, CA) in DM patients. Methods and Results: This was a subanalysis from the GHOST-EU (Gauging coronary Healing with biOresorbable Scaffolding plaTforms in Europe) multicenter retrospective registry including patients treated with Absorb BVS between November 2011 and September 2014. In this study, a comparative analysis stratified according to DM was performed. The primary endpoint was target lesion failure (TLF), defined as the combination of cardiac death, target-vessel myocardial infarction (MI) and clinically-driven target-lesion revascularization (TLR). A total of 1,477 patients were treated with 2,224 Absorb BVS; 381 (25.8%) and 1,096 (74.2%) patients were with and without DM, respectively. The 1-year rate of TLF was higher among patients with DM (7.8%) than those without DM (4.3%); the increase in TLF was driven by TLR (6.5% vs. 3.3%, P = 0.009); no significant differences in cardiac death (1.1% vs. 0.9%, P = 0.68) and target-vessel MI (3.1% vs. 2.2%, P = 0.38) were observed, respectively. Definite/probable scaffold thrombosis rate tended to be higher among patients with DM than those without DM (3.0% vs. 1.7%, P = 0.14, respectively). Conclusions: Absorb BVS use in patients with DM was associated with increased 1-year TLF and scaffold thrombosis compared with non-diabetes patients.
KW - bioresorbable vascular scaffolds
KW - clinical outcomes
KW - diabetes
UR - http://www.scopus.com/inward/record.url?scp=85032220216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032220216&partnerID=8YFLogxK
U2 - 10.1002/ccd.27388
DO - 10.1002/ccd.27388
M3 - Article
C2 - 29068130
AN - SCOPUS:85032220216
SN - 1522-1946
VL - 91
SP - 444
EP - 453
JO - Catheterization and Cardiovascular Interventions
JF - Catheterization and Cardiovascular Interventions
IS - 3
ER -